05/28/2026
In a mere 6 months we’ve seen the black box warning removed from estrogen products and the renaming of Poly-cystic ovarian syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS), a major re-brand that strongly reflects the metabolic involvement related to this syndrome.
Both changes are a major win for women and reflect shifting attitudes in what it means to be healthy.
In the case of estrogen products, women are now able to benefit from the cardio-protective, bone strengthening, cognition improving effects without the erroneous fear of increased cancer, blood clots or heart disease.
The change to PMOS feels more significant in that this is a recognition of the fact that the condition extends far beyond ovarian cysts or reproductive symptoms alone. For many women, the most significant drivers are rooted in insulin resistance, inflammation, metabolic dysfunction, stress physiology, and hormone signaling throughout the entire body.
Names matter. Language shapes perception, both in healthcare and in the way patients understand themselves. For years, many women were told their symptoms were simply a gynecologic issue, a cosmetic concern, or something to “just live with.” These shifts reflect a broader movement toward recognizing women’s health as deeply interconnected, metabolic, neurological, cardiovascular, and whole-body in nature.
We are slowly moving away from reductionist medicine that isolates symptoms into silos and toward a more integrated understanding of health. And while there is still a long way to go, these changes feel like meaningful steps in the right direction.
